Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$16.51 +2.63%

+$0.41 today

Market cap
$3.65B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 2.43M

Average 3.70M

RLAY Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Relay Therapeutics, Inc.NASDAQ: RLAY

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 100.0%

Gross margin was 100.0% in Q2 FY2026, up 9080.1 pp from a year earlier. On a trailing-twelve-month basis it was -566.6%, up 1757.0 pp year over year. Over 3 fiscal years it widened by 17573.1 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+16.8 pp QoQ
Last fiscal yearDec 2025
76.8%+3129.0 pp YoY
LTMJun 2026
-566.6%+1757.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+9080.1 pp——
1 year+3129.0 pp——
3 years+17573.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
76.8%
Year-over-year change
+3129.0pp

Gross Margin vs competitors

How RLAY compares with its peers on the latest reported figures

  • RLAY's LTM Jun 2026 gross margin of -566.6% is the lowest of the 6 companies compared; the peer median is 96.3%.
  • Its year-over-year change of +1757.0 pp is the highest of 6, against a peer median of +6.6 pp.
  • Over three fiscal years its change of +17573.1 pp compares with a peer median of +1.0 pp.
RLAY Competitors Peer median
Gross Margin for RLAY and competitors
Company Period LTM level YoY 3-year change
KYMRKymera Therapeutics, Inc.LTM Jun 2026102.0% +6.6 pp+0.0 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
TNGXTango Therapeutics, Inc.FY202596.3% -3.7 pp-3.7 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-8.7% +943.2 pp+2.0 pp
RLAYRelay Therapeutics, Inc.LTM Jun 2026-566.6% +1757.0 pp+17573.1 pp
RVMDRevolution Medicines, Inc.FY2025— ——
ERASErasca, Inc.FY2025— ——
TYRATyra Biosciences, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
Peer median (excluding RLAY) 96.3%+6.6 pp+1.0 pp

Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.03M1.38M25.55M10.01M15.36M
Cost of Revenue169.39M243.01M326.39M315.44M3.56M
Gross Profit(166.36M)(241.62M)(300.84M)(305.43M)11.8M
Gross Margin-5492.2%-17496.3%-1177.6%-3052.2%76.8%
Research & Development295.65M246.36M330.02M319.09M261.38M
Selling, General & Admin59.75M69.33M78.58M80.24M56.71M
Operating Expenses198.34M57.65M72.16M67.03M314.54M
Depreciation & Amortization3.93M4.13M5.27M5.46M3.56M
EBITDA(223.08M)(306.82M)(374.15M)(380.21M)(272.92M)
EBITDA Margin-7364.9%-22217.4%-1464.6%-3799.4%-1777.4%
Operating Income(364.7M)(299.28M)(373M)(372.47M)(302.74M)
Operating Margin-12040.2%-21670.9%-1460.1%-3722.1%-1971.6%
Interest Income830K8.79M31.05M34.75M27.04M
Interest Expense00000
Other Income / Expenses826K8.77M31.03M34.76M26.26M
Income Before Tax(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Pre-Tax Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
Income Tax Expense00000
Net Income(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Net Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
EPS (Basic)(3.82)(2.59)(2.79)(2.36)(1.61)
EPS (Diluted)(3.82)(2.59)(2.79)(2.36)(1.61)
Weighted Avg Shares95.14M112.23M122.58M142.87M171.59M
Weighted Avg Shares (Diluted)95.14M112.23M122.58M142.87M171.59M

Relay Therapeutics, Inc.

NASDAQ:RLAY

Intrinsic Alpha fair value

Locked

Current Price

$16.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.